LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Akciju saraksts・AnaptysBio Inc

AnaptysBio Inc

Slēgts

SektorsVeselības aprūpe

60.29 1.06

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

59.39

Max

60.97

Galvenie mērījumi
By Trading Economics
Ienākumi	-102M -53M
Pārdošana	-83M 26M
Peļņas marža	-206.934
Darbinieki	104
EBITDA	-102M -34M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+35.97% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-219M 1.8B
Iepriekšējā atvēršanas cena	59.23
Iepriekšējā slēgšanas cena	60.29

Ziņu noskaņojums

By Acuity

50%

159 / 345 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

19.25 / 21.135 Atbalsts un pretestība

AnaptysBio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. maijs 23:31 UTC

Karstas akcijas

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

2026. g. 20. maijs 22:52 UTC

Galvenie tirgus virzītāji

Osisko Shares Fall on Planned Convertible Notes Offering

2026. g. 20. maijs 23:47 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. maijs 23:47 UTC

Tirgus saruna

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026. g. 20. maijs 23:44 UTC

Peļņas

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

2026. g. 20. maijs 23:35 UTC

Tirgus saruna

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

2026. g. 20. maijs 23:30 UTC

Tirgus saruna

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

2026. g. 20. maijs 23:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. maijs 23:17 UTC

Tirgus saruna

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

2026. g. 20. maijs 23:15 UTC

Tirgus saruna

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

2026. g. 20. maijs 23:14 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

2026. g. 20. maijs 23:02 UTC

Tirgus saruna

KMD Brands Faces Two Testing Hurdles -- Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Infratil's Other Assets Deserve Attention, Too -- Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 20. maijs 22:57 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 20. maijs 22:51 UTC

Tirgus saruna

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

2026. g. 20. maijs 22:51 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. maijs 22:27 UTC

Tirgus saruna

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

2026. g. 20. maijs 22:14 UTC

Tirgus saruna

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

2026. g. 20. maijs 22:10 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

2026. g. 20. maijs 22:00 UTC

Peļņas

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

2026. g. 20. maijs 21:38 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

2026. g. 20. maijs 21:27 UTC

Peļņas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

2026. g. 20. maijs 21:20 UTC

Peļņas

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

2026. g. 20. maijs 21:19 UTC

Peļņas

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

2026. g. 20. maijs 21:18 UTC

Peļņas

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

2026. g. 20. maijs 21:17 UTC

Peļņas

Nvidia's Vera CPU Opens New $200B Market, CFO Says

2026. g. 20. maijs 21:16 UTC

Peļņas

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

AnaptysBio Inc Prognoze

Cenas mērķis

By TipRanks

35.97% augšup

Prognoze 12 mēnešiem

Vidējais 81.27 USD 35.97%

Augstākais 140 USD

Zemākais 50 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

19.25 / 21.135Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

159 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.